Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Instruments at Analytica 2014

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Malvern Instruments shows how complementary technologies solve analytical challenges from biopharm to bulk materials.

Malvern Instruments growing range of analytical instrumentation now includes extended solutions for characterization at the nanoscale and an expanded portfolio for those working in preformulation and formulation development in the biopharmaceuticals sector. At Analytica 2014 (1-4 April, Munich, Germany) Malvern will demonstrate how using complementary technologies to address analytical challenges, across many different industry sectors and applications, delivers the detailed information and understanding required to engineer efficient processes and high quality products.
 
Malvern recently announced an exclusive global distribution agreement with Rheosense Inc. to promote, market sell and support the VROC product range into industrial markets. The m-VROCi, a new microfluidic Viscometer/Rheometer On a Chip, will be on the Malvern stand for first time in Europe at Analytica.
 
Malvern’s acquisition of NanoSight in 2013 means that NanoSight Nanoparticle Tracking Analysis (NTA) systems will also be exhibited on the Malvern stand at Analytica for the first time. Together with the established Zetasizer and Viscotek GPC/SEC systems, and the new Archimedes and Viscosizer 200 instruments, the NanoSight NTA range further strengthens Malvern’s offering of orthogonal technologies for characterization at the nanoscale. The result is a toolbox of complementary systems that support today’s diverse characterization needs, from nanoparticles to proteins and beyond.
 
Visitors to the Malvern stand can also learn about the complementarity of Mastersizer 3000 laser diffraction particle size analysis and Morphologi G3-ID image analysis based particle characterization and chemical identification, for the elucidation of complex materials such as pharmaceutical blends.
 
Rheology and viscometry solutions support many aspects of materials understanding and Malvern will show the Kinexus rotational rheometer, and the new Viscosizer 200, whose high throughput analysis of small volume samples is proving highly suitable for viscosity screening at the all important pre-formulation stage of developing large molecule drugs.
 
The new Viscotek SEC-MALS 20 detector is the latest addition to Malvern’s range of GPC/SEC products. Viscotek gel permeation/size exclusion chromatography (GPC/SEC) systems measure absolute molecular weight, mass, size, concentration and the molecular structure of proteins, polymers and other macromolecules.
 
Visit Malvern in Hall A1, Stand 227 at Analytica 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern takes ACHEMA Visitors from R&D Through to Product QC
Visitors to the Malvern Instruments stand at ACHEMA 2012 will see how the company’s range of complementary materials characterization technologies and instrumentation support the needs of manufacturing industry.
Wednesday, March 28, 2012
Malvern Scientists will lead Protein Characterization Workshop at PEGS Summit
Drs Kevin Mattison, Ulf Nobbmann and Jason Sanchez will lead a workshop at the 7th Annual PEGS.
Tuesday, September 13, 2011
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!